


Forge Biologics Strengthens Genetic Medicine CDMO Capabilities









Forge Biologics Receives PRIME Designation from EMA for Novel Gene Therapy









Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency for novel gene therapy FBX-101









Regulatory actions for Jan. 18, 2023









Forge Biologics receives EMA PRIME designation for Krabbe disease drug









Krabbe Disease Gene Therapy Receives EMA PRIME Designation









Top Columbus Startups Watch in 2023








